Archives: 2020-10-26

PIER MARIA FORNASARI
2020-10-26

FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy in non-Hodgkin’s Lymphoma.

Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin’s lymphoma Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ADI-001,

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2020-10-25

COVID-19 and Lombardy: TESTing the impact of the first wave of the pandemic. Seroprevalence in the Bergamo area is 38.5%.

The emergence of a novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused a major disease outbreak that posed a threat to public health worldwide. Among the western countries, Italy was the first to experience a vast Coronavirus Disease 2019 (COVID-19) outbreak and the province of Bergamo experienced the deadliest COVID-19 outbreak in theworld. Due

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-10-24

Researchers of NEI use gene therapy and a novel light-sensing protein to restore vision in mice

NIH-funded therapy will now be tested in humans A newly developed light-sensing protein called the MCO1 opsin restores vision in blind mice when attached to retina bipolar cells using gene therapy. The National Eye Institute, part of the National Institutes of Health, provided a Small Business Innovation Research grant to Nanoscope, LLC for development of

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2020-10-24

Masks could cut COVID-19 deaths in the US by 130,000: IHME COVID-19 Forecasting Team study shows

Even if state-level governments in the United States reimpose limited social distancing measures to halt the spread of COVID-19, the death toll could more than double by the end of February 2021 to 511,000, according to projections released Friday. Near-universal mask wearing over the coming months could reduce that grim tally by nearly 130,000, researchers

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-10-24

Neutrophils express non-canonical functions, including vascular repair and hematopoietic homeostasis.

Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have discovered that neutrophils, the most abundant cells of the innate immune system, have many more functions in the body than previously thought. This finding suggests possible new treatments for many diseases, including cancer. In a study published in the journal Cell, the research team demonstrates that

Read More

No Comments InREGENERATIVE MEDICINE
PIER MARIA FORNASARI
2020-10-23

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Researchers have identified a second receptor that might be important in SARS-CoV-2 infectivity, according to a new report published in Science on October 20. This cofactor helps facilitate virus-host cell interactions in cells with low levels of angiotensin-converting enzyme 2 (ACE2), the primary receptor on host cells, and might explain the increased pathogenicity of SARS-CoV-2. Why is

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-10-23

In an open label phase II multicentre randomised controlled trial (PLACID Trial) convalescent plasma isn’t associated with a reduction in disease progression or all cause mortality in moderate Covid-19.

Convalescent plasma may not prevent progression to severe disease or reduce mortality risk in hospitalized patients with moderate COVID-19, based on a phase 2 trial involving more than 400 patients in India. The PLACID trial offers real-world data with “high generalizability,” according to lead author Anup Agarwal, MD, of the Indian Council of Medical Research,

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-10-14

SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF-barrier in human brain organoids.

Coronavirus disease-19 (COVID-19), caused by the SARS-CoV-2 virus, leads to respiratory symptoms that can be fatal. However, neurological symptoms have also been observed in some patients. The cause of these complications is currently unknown. In this paper, were use human pluripotent stem cell-derived brain organoids to examine SARS-CoV-2 neurotropism. Was found expression of viral receptor

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-10-13

NIH launched the ACTIV-5/BET study, a randomized, double-blind, placebo-controlled trial testing risankizumab or lenzilumab +remdesivir in Covid-19 treatment.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and merit advancement into larger clinical trials. The ACTIV-5 Big Effect Trial, which will enroll adult volunteers hospitalized

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-10-13

Therapeutic Management of Patients with COVID-19. Updated Treatment Guidelines released by NIH.

A number of investigational agents and drugs that are approved for other indications are currently being studied in clinical trials for the treatment of COVID-19 and associated complications. Data from randomized controlled trials, prospective and retrospective observational cohorts, and case series studies are rapidly emerging. The COVID-19 Treatment Guidelines Panel (the Panel) continues to review

Read More

No Comments InCovid-19